BACKGROUND - Numerous genetic variants have been confirmed as prostate cancer risk factors. These variants may confer susceptibility to the development of specific molecular alterations during tumor initiation and progression.
The TMPRSS2:ERG gene fusion occurs in roughly 50% of prostate cancers. Genetic risk variants may influence the development of this fusion. We sought to determine whether prostate cancer risk variants are differentially associated with TMPRSS2:ERG fusion positive and negative cancer.
METHODS - In the Health Professionals Follow-up Study and Physicians' Health Study Tumor Cohort, we evaluated the associations of 39 prostate cancer risk single nucleotide polymorphisms (SNPs) with TMPRSS2:ERG fusion status, measured by ERG protein expression. Logistic regression was performed to generate odds ratios and 95% confidence intervals. The primary outcome was ERG+ (n=227) versus ERG- (n=260) prostate cancer. A secondary outcome was ERG+ or ERG- cancer versus controls without cancer.
RESULTS - Six of the 39 SNPs were significantly associated (p<0.05) with ERG+ versus ERG- disease. Three SNPs were exclusively associated with the risk of ERG+, one with risk of ERG-, and two with associations trending in opposite directions for ERG+ and ERG-. Only two significant SNPs would be expected by chance.
CONCLUSIONS - Prostate cancer genetic risk variants are differentially associated with the development of ERG+ and ERG- prostate cancer.
IMPACT - Our findings suggest the molecular process of prostate carcinogenesis may be distinct for men with different underlying genetic predisposition. When examining risk factors for prostate cancer, the integration of molecular subtypes may enhance understanding of the etiology of this disease.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2016 Mar 03 [Epub ahead of print]
Kathryn L Penney, Andreas Pettersson, Irene M Shui, Rebecca E Graff, Peter Kraft, Rosina T Lis, Howard D Sesso, Massimo Loda, Lorelei A Mucci
Channing Division of Network Medicine, Department of Epidemiology, Brigham and Women's Hospital/Harvard Medical School, Harvard T.H. Chan School of Public Health Department of Epidemiology, Harvard School of Public Health., Fred Hutchinson Cancer Research Center., Epidemiology & Biostatistics, University of California, San Francisco., Department of Epidemiology, Harvard TH Chan School of Public Health., Department of Pathology, Dana-Farber Cancer Institute., Division of Preventive Medicine, Department of Medicine, , Brigham and Women's Hospital, Harvard Medical School., Department of Medical Oncology, Dana-Farber Cancer Institute., Channing Division of Network Medicine, Department of Epidemiology, Brigham and Women's Hospital/Harvard Medical School, Harvard T.H. Chan School of Public Health.